Core Viewpoint - The announcement highlights the FDA approval of the clinical trial registration application for TUL108, a novel broad-spectrum β-lactamase inhibitor developed by the company, which is expected to enhance its competitive position in the anti-infection field [1] Group 1: Product Development - The clinical trial registration application (IND) for TUL108 was approved by the FDA, with IND number 178724, set to commence on January 28, 2026 [1] - TUL108 is designed to treat infections caused by both Gram-negative and Gram-positive bacteria, including complicated urinary tract infections (cUTI), complicated intra-abdominal infections (cIAI), lung infections, and bloodstream infections [1] - The drug shows high sensitivity against carbapenem-resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, providing comprehensive coverage for clinically urgent Gram-negative bacteria resistant to carbapenems [1] Group 2: Strategic Implications - The development of TUL108 is expected to strengthen the company's position in the anti-infection sector [1] - The company aims to continue its commitment to new product development, enhancing its competitiveness and creativity within the pharmaceutical industry [1] - The anticipated success of TUL108 is projected to generate greater returns for the company and its shareholders [1]

Summary of the Conference Call Records Company Overview - **Company**: Xiansheng Pharmaceutical (先声药业) - **Industry**: Biopharmaceuticals, specifically focusing on innovative drug development for inflammatory bowel disease (IBD) Key Points and Arguments Partnership and Collaboration - On January 27, 2026, Xiansheng Pharmaceutical announced a licensing and collaboration agreement with Boehringer Ingelheim to jointly develop the preclinical dual-specific antibody SIM0709 targeting TL1A and IL-23 for the treatment of IBD [1] - Xiansheng Pharmaceutical will receive an upfront payment of €42 million, with potential milestone payments reaching up to €1.016 billion based on development, registration, and commercial success [1] Product Development and Pipeline - SIM0709 is developed from Xiansheng's multi-antibody technology platform and has shown superior efficacy in both in vitro and in vivo studies compared to the combination of two single drugs [2] - The company has 10 approved innovative drugs and over 60 projects in its R&D pipeline, with expectations to approve 2-3 new innovative drugs annually [2] - Upcoming approvals include Enlitaz (injection of rituximab β) and Xianbixin sublingual tablets in 2024, and Enzeshun (injection of suvezatamab, VEGF) and the insomnia treatment Daliresheng in 2025 [2] Business Development and Market Position - As of January 2026, Xiansheng Pharmaceutical has achieved 5 technology licensing agreements for early-stage self-developed innovative drugs, with a total potential transaction value exceeding $4.6 billion [2] - The company has successfully established its ADC (Antibody-Drug Conjugate) and TCE (T-cell Engager) platforms, with ongoing clinical pipeline advancements and business development collaborations [3] Financial Performance and Shareholder Returns - Xiansheng Pharmaceutical maintains a solid core business with high dividend payouts and shareholder returns, indicating strong R&D contributions and potential for upward elasticity [3] Additional Important Information - Over 3 million people globally are affected by inflammatory bowel disease (IBD), highlighting the significant market potential for SIM0709 and similar treatments [2] - The innovative drug matrix of Xiansheng Pharmaceutical is rich, with multiple blockbuster products expected to be approved in the near future, reinforcing the company's growth trajectory [2]

Group 1: Shareholding Increase Plan - The controlling shareholder, Jiujiang Group, holds 307,522,643 shares, accounting for 50.97% of the total share capital of the company [2] - Jiujiang Group plans to increase its shareholding from February 1, 2026, to July 31, 2026, with a total investment of no less than RMB 300 million and no more than RMB 500 million [2] - The increase will be executed through the Shanghai Stock Exchange trading system without a set price range, depending on stock price fluctuations and market trends [2][3] Group 2: Clinical Trial Announcement - The company has completed the enrollment of the first subject in the Phase I clinical trial of PZH2113 capsules, which is expected to have no significant impact on the company's financial status and operating performance for the year [10] - PZH2113 capsules are a Class 1 innovative drug with independent intellectual property rights, targeting relapsed/refractory non-Hodgkin lymphoma [10][12] - The global market for diffuse large B-cell lymphoma is projected to exceed USD 20 billion by 2030, indicating a significant unmet clinical need [12]

作为新一轮科技革命和产业变革的重要驱动力量，以AI、大数据为代表的新一代信息技术与医药健康 领域的交叉融合，正加速推动医学基础研究、临床应用研究以及药械研发进程。 刘伟谈到，在"AI+病理"和"AI+制药"等应用场景中，我们明显感受到人工智能正从早期探索逐步走向 辅助决策和效率提升的实用阶段。在病理领域，AI在数字病理图像分析、标准化判读和一致性提升方 面的价值逐步显现，有助于缓解病理医生资源紧张、降低主观差异，公司在相关投资项目上也曾关注过 此类标的。 2025年，北京市医疗保障局、北京市卫生健康委员会等九部门联合印发《北京市支持创新医药高质量发 展若干措施（2025年）》（以下简称"新32条"），将临床试验审评审批时限大幅压缩，更在市场准入、 医保支付、投融资支持及生产智造升级等环节同步推出务实举措。 来自科学技术界的市政协委员、北京嘉林药业股份有限公司总裁刘伟谈到，"新32条"措施，从研、产、 审、用全链条加强了对创新药械的支持，解决了制约行业发展的一系列痛点问题，可以感受到北京对医 药创新的支持更系统、更务实，既为医药制造升级指明了前瞻性方向，也为创新药从研发到成果转化营 造了良好的产业环境。 在刘伟 ...

Core Viewpoint - The collaboration between Xiansheng Pharmaceutical and Boehringer Ingelheim aims to develop the dual-specific antibody SIM0709 for the treatment of inflammatory bowel disease, with potential milestone payments reaching up to €1.058 billion [1][2] Group 1: Collaboration Details - Xiansheng Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Boehringer Ingelheim for the development of SIM0709 [1] - Boehringer Ingelheim will obtain global rights outside Greater China, while Xiansheng Pharmaceutical will receive an upfront payment and milestone payments based on development, registration, and commercialization [1] - The total potential transaction amount for this collaboration could exceed €1.058 billion, along with royalties from net sales outside Greater China [1][2] Group 2: Product Information - SIM0709 is a long-acting humanized dual-specific antibody developed on Xiansheng Pharmaceutical's multi-antibody technology platform, targeting TNF-like cytokine 1A and IL-23 to block key pathways in inflammatory bowel disease [1] - Existing data shows that SIM0709 has demonstrated excellent synergistic effects in both in vitro primary cell experiments and in vivo animal studies [1] Group 3: Company Strategy and Financials - This collaboration marks Xiansheng Pharmaceutical's second overseas licensing project for an innovative drug in the field of autoimmune diseases and the fifth self-developed innovative drug to achieve external technology licensing [2] - The cumulative potential transaction amount from these licensing agreements has exceeded $4.6 billion [2] - Xiansheng Pharmaceutical has significantly increased its R&D investment, totaling approximately ¥9 billion over the past five years, with the proportion of revenue from innovative drugs rising from 45% in 2020 to 77% in the first half of 2025 [2]

Core Viewpoint - The company has announced the initiation of Phase I clinical trials for its innovative drug PZH2113 capsules, targeting relapsed/refractory non-Hodgkin lymphoma, marking a significant advancement in its oncology portfolio [1][3]. Group 1: Clinical Development - PZH2113 capsules have completed the first subject enrollment in Phase I clinical trials, officially entering the clinical research phase [1]. - The drug is designed for relapsed/refractory non-Hodgkin lymphoma, specifically targeting diffuse large B-cell lymphoma, with a clinical trial approval expected by June 2024 [1][2]. - The Phase I trial consists of an open-label, non-randomized, multi-center design, divided into Part A (dose escalation and expansion) and Part B (cohort expansion) [1]. Group 2: Market Context - The incidence of non-Hodgkin lymphoma in China is on the rise, with over 90% of approximately 100,000 new cases of malignant lymphoma in 2020 being non-Hodgkin lymphoma [2]. - There is a significant unmet clinical need for effective treatments for relapsed/refractory non-Hodgkin lymphoma, as current first-line therapies have a 30%-40% recurrence rate [2]. - The global market for diffuse large B-cell lymphoma is projected to exceed $20 billion by 2030, indicating substantial market potential for new therapies [2]. Group 3: Strategic Implications - The entry of PZH2113 capsules into Phase I clinical trials represents a critical step in the company's strategy to enhance its oncology treatment offerings [3]. - Successful development and approval of PZH2113 could diversify the company's product line and strengthen its competitive position in the oncology market [3].

Core Insights - The innovative drug Shuwotini tablets, which targets a rare mutation in non-small cell lung cancer, has won the first prize in Jiangsu Province's Science and Technology Progress Award, highlighting its significant breakthrough in original innovation and clinical application [1] - Shuwotini tablets are the first and only drug approved for the EGFR 20 insertion mutation, receiving market approval in China in August 2023 and subsequently being included in the national medical insurance directory, significantly reducing patient costs [1] - The award recognizes the project's contributions to technological innovation and its impact on economic and social development, emphasizing the comprehensive strength of the research and development company in key technology breakthroughs and results transformation [1] Company and Industry Developments - The company, Dizhe Pharmaceutical, aims to continue addressing unmet clinical needs through technological innovation, accelerating the delivery of globally competitive original innovations to benefit patients worldwide [2] - The drug is expected to gain international recognition, as it was approved by the U.S. FDA in 2025, marking it as the first independently developed innovative drug from China to be approved in the U.S. and included in the National Comprehensive Cancer Network guidelines for non-small cell lung cancer [1]

Core Insights - The collaboration between Sihuan Pharmaceutical and Boehringer Ingelheim aims to develop the dual-specific antibody SIM0709 for the treatment of inflammatory bowel disease (IBD) [2][3] - The agreement grants Boehringer Ingelheim global rights outside Greater China, with Sihuan Pharmaceutical receiving an upfront payment of €42 million and potential milestone payments up to €1.016 billion [2][4] - The partnership is expected to leverage Sihuan's innovative research capabilities and Boehringer Ingelheim's global development and commercialization strengths to accelerate the development of this innovative therapy [3][4] Company Developments - SIM0709 is developed from Sihuan's multi-antibody technology platform and targets two key pathways involved in IBD, showing superior efficacy in preclinical studies compared to existing therapies [3] - This collaboration marks Sihuan's second overseas licensing project in the autoimmune disease sector and the fifth self-developed innovative drug to be licensed out, with total potential transaction amounts exceeding $4.6 billion [4] - Sihuan has significantly increased its R&D investment, totaling approximately 9 billion RMB over the past five years, with the proportion of revenue from innovative drugs rising from 45% in 2020 to 77% in the first half of 2025 [4] Market Context - Over 3 million people globally are affected by IBD, highlighting a significant unmet clinical need in this therapeutic area [2] - The collaboration is positioned to redefine effective treatment methods and improve the quality of life for patients suffering from IBD [2][3]

Group 1: AI Empowerment and Digital Transformation - The company is implementing its digital development plan (2022-2026) by leveraging data and AI technologies across key segments of the supply chain, enhancing operational efficiency and business innovation [2] - The self-developed "Marketing Business Operation Platform" has been piloted in the pharmaceutical business group, improving order processing and cost accounting, leading to a 30% reduction in manual workload and saving 60,000 paper documents annually [3] - The "One Product, One Code Traceability Platform" has been developed for traditional Chinese medicine, providing digital identity for authentic medicinal materials [2] Group 2: Supply Chain and Operational Efficiency - The company has achieved 100% automation in settlement processes, reducing the cycle from 30 days to real-time [3] - The establishment of 90 standard processes and 60 management indicators supports business decision-making effectively [3] - The "Smart Cloud Medicine" platform and "One Product, One Chain" model have created a closed-loop system covering all aspects from resource management to payment, significantly improving supply chain collaboration and management [3] Group 3: Research and Development Progress - The tumor organ library and molecular marker research projects have yielded results published in Cancer Cell and Chinese Clinical Oncology journals [4] - The INR101 diagnostic nuclear medicine project has entered phase III clinical trials, with 32 research centers established and 60 subjects enrolled [5] - The INR102 therapeutic nuclear medicine project has received a clinical trial notification, with phase I trials initiated and 12 patients enrolled [6] Group 4: Dividend Distribution - For the 2024 fiscal year, the company will distribute a cash dividend of 11.85 CNY per 10 shares, totaling 2,164,310,537.44 CNY, which represents 90.09% of the net profit attributable to shareholders [7] - The total cash dividend for 2024, including a special dividend, amounts to 23.98 CNY per 10 shares, with a total of 4,278,661,722.00 CNY distributed [7] - In the first half of 2025, a cash dividend of 10.19 CNY per 10 shares will be distributed, totaling 1.818 billion CNY, representing 50.05% of the net profit for that period [7] Group 5: Online Sales Performance - The pharmaceutical business group has seen over a 20% increase in O2O sales in the first half of 2025, aided by online content marketing [8] - The company generated 2.54 billion CNY in GMV from e-commerce platforms, attracting 4.845 million visitors and converting 3.54 million consumers [9] - Yunnan Baiyao toothpaste holds the number one market share in the domestic channel for 2025, while the brand ranked first in Tmall for anti-hair loss shampoo during the "618" shopping festival [9]

智通财经APP讯，康希诺生物(06185)发布公告，根据中国企业会计准则，预计截至2025年12月31日止年 度本集团实现营业收入人民币10.4亿元到人民币10.8亿元，与上年同期相比，将增加人民币1.94亿元到 人民币2.34亿元，同比增长22.88%到27.61%。 预计截至2025年12月31日止年度实现归属于母公司所有者的净利润为人民币2450万元到人民币2900万 元，与上年同期相比，将实现扭亏为盈。 预计截至2025年12月31日止年度实现归属于母公司所有者扣除非经常性损益后净亏损为人民币9100万元 到人民币9600万元。 报告期内，本集团持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫 苗曼海欣收入保持持续增长。同时，本集团深入推进降本增效，各项费用得到有效管控;产销协同进一 步优化，毛利率亦有所提升。整体盈利能力显著提升，成功于本报告期实现归属于母公司所有者的净利 润为正。 报告期内，随着本集团研发项目的快速推进及国际合作的开展，本集团获得了更多政府专项补助及国际 专项资金的支援，故于本报告期产生较大金额的非经常性收益。 ...